Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Open Innovation for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Due Diligence
Comparison
 
Due Diligence
Overview
Top Applications
Online Panel Discussions
Request Consultation
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
In-licensing

CNS late stage or marketed product opportunities

Azur Pharma
Azur is interested in late stage or marketed products for the US market

Full description

Azur Pharma has a 50 person CNS (Pysch) sales force. We are interested in acquiring or licensing US marketed products that we can use to leverage our current sales infrastructure.

Azur is also interested in developing its pipeline in the area of CNS mainly in the Pysch or Neurology fields. Our focus would be on late stage opportunities, i.e. Phase III or in registration.

We also have a preference for opportunities with lower clinical risk and are happy to look at projects such as reformulations of existing treatments.

 

Development status

Phase III/IV

Type of business relationship sought

Azur is interested in acquisitions or licensing. As a private company we retain flexibility on the structuring of transactions.

Research Partnership for Due Diligence Execution
Biobusiness 2009
Yissum Technology Transfer Hebrew University
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2009 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us